699856 | FP-18, sodium salt
(2R,3R,4R,5S,6R)-3-dodecanamido-4,5-bis(dodecanoyloxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl phosphate, sodium salt
Please Confirm Your Location
Effective March 1, 2018, Merck KGaA, Darmstadt, Germany* is the exclusive Distributor of Avanti Research. Research Products for all countries except the United States. For product pricing and order placement, please click on the appropriate Location Box below.
For customers located outside the United States, you will be redirected to www.sigmaaldrich.com/avanti prior to completing your purchase. Thank you for your continued business and support of Avanti Research!
*The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada
FP-18, sodium salt
(2R,3R,4R,5S,6R)-3-dodecanamido-4,5-bis(dodecanoyloxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl phosphate, sodium salt
FP adjuvants, particularly FP-18 and FP-20, offer another innovative approach to boosting vaccine efficacy by selectively stimulating Toll-like receptor 4 (TLR4) pathways. The simplicity of FP structures allows for scalable production of highly pure materials, ensuring a reliable and cost-effective supply for vaccine developers. Like VSA, FP adjuvants provide both humoral and cellular immune enhancements but achieve this through a targeted, mechanism-driven approach. FP-18 activates the MyD88-dependent pathway, leading to the release of critical cytokines such as TNFα, IL-1β, and IL-6. It also stimulates the TRIF-dependent pathway, which promotes a Type 1 interferon (IFN) signature, an essential component for antiviral responses.
FP-18, sodium salt (and other FP compounds) have been licensed through a third-party. This compound is intended for research purposes only. If you wish to discuss a potential sub-license, please reach out via email to customerservice@avantilipids.com.
C42H78NNa2O11P
C 59.35%, H 9.25%, H 1.65%, Na 5.41%, O 20.70%, P 3.64%
CAS Registry Number is a Registered Trademark of the American Chemical Society
Powered by BiozJ. Med. Chem. 2023, 66, 4, 3010–3029Publication Date:February 2, 2023https://doi.org/10.1021/acs.jmedchem.2c01998
ACS Omega 2023, 8, 39, 36412–36417Publication Date:September 18, 2023https://doi.org/10.1021/acsomega.3c05363
J. Med. Chem. 2021, 64, 16, 12261–12272Publication Date:August 12, 2021https://doi.org/10.1021/acs.jmedchem.1c00896
- Certificate of Analysis (Lot No. 699856P-10MG-A-010 and 7187PIA010)
